BACKGROUND: The appropriate use of adjuvant therapy in patients with gross totally resected atypical meningioma requires an accurate assessment of recurrence risk. We sought to determine whether cytogenetic/genetic characterization may facilitate better estimation of the probability of recurrence. METHODS: We first analyzed our clinical database, including high-resolution DNA copy number data, to identify 11 common copy number aberrations in a pilot cohort of meningiomas of all grades. We summed these aberrations to devise a cytogenetic abnormality score (CAS) and determined the CAS from archived tissue of a separate cohort of 32 patients with gross totally resected atypical meningioma managed with surgery alone. Propensity score adjusted Cox regression was used to determine whether the CAS was predictive of recurrence. RESULTS: An association between higher CAS and higher grade was noted in our pilot cohort with heterogeneity among atypical tumors. Among the 32 patients who underwent gross total resection of an atypical meningioma, the CAS was not significantly associated with age, gender, performance status, or tumor size/location but was associated with the risk of recurrence on univariable analysis (hazard ratio per aberration = 1.52; 95% CI = 1.08-2.14; P = .02). After adjustment, the impact of the dichotomized number of copy aberrations remained significantly associated with recurrence risk (hazard ratio = 4.47; 95% CI = 1.01-19.87; P = .05). CONCLUSIONS: The number of copy number aberrations is strongly associated with recurrence risk in patients with atypical meningioma following gross total resection and may inform the appropriate use of adjuvant radiation therapy in these patients or be useful for stratification in clinical trials.
BACKGROUND: The appropriate use of adjuvant therapy in patients with gross totally resected atypical meningioma requires an accurate assessment of recurrence risk. We sought to determine whether cytogenetic/genetic characterization may facilitate better estimation of the probability of recurrence. METHODS: We first analyzed our clinical database, including high-resolution DNA copy number data, to identify 11 common copy number aberrations in a pilot cohort of meningiomas of all grades. We summed these aberrations to devise a cytogenetic abnormality score (CAS) and determined the CAS from archived tissue of a separate cohort of 32 patients with gross totally resected atypical meningioma managed with surgery alone. Propensity score adjusted Cox regression was used to determine whether the CAS was predictive of recurrence. RESULTS: An association between higher CAS and higher grade was noted in our pilot cohort with heterogeneity among atypical tumors. Among the 32 patients who underwent gross total resection of an atypical meningioma, the CAS was not significantly associated with age, gender, performance status, or tumor size/location but was associated with the risk of recurrence on univariable analysis (hazard ratio per aberration = 1.52; 95% CI = 1.08-2.14; P = .02). After adjustment, the impact of the dichotomized number of copy aberrations remained significantly associated with recurrence risk (hazard ratio = 4.47; 95% CI = 1.01-19.87; P = .05). CONCLUSIONS: The number of copy number aberrations is strongly associated with recurrence risk in patients with atypical meningioma following gross total resection and may inform the appropriate use of adjuvant radiation therapy in these patients or be useful for stratification in clinical trials.
Authors: Meike W Vernooij; M Arfan Ikram; Hervé L Tanghe; Arnaud J P E Vincent; Albert Hofman; Gabriel P Krestin; Wiro J Niessen; Monique M B Breteler; Aad van der Lugt Journal: N Engl J Med Date: 2007-11-01 Impact factor: 91.245
Authors: Shakti H Ramkissoon; Wenya Linda Bi; Steven E Schumacher; Lori A Ramkissoon; Sam Haidar; David Knoff; Adrian Dubuc; Loreal Brown; Margot Burns; Jane B Cryan; Malak Abedalthagafi; Yun Jee Kang; Nikolaus Schultz; David A Reardon; Eudocia Q Lee; Mikael L Rinne; Andrew D Norden; Lakshmi Nayak; Sandra Ruland; Lisa M Doherty; Debra C LaFrankie; Margaret Horvath; Ayal A Aizer; Andrea Russo; Nils D Arvold; Elizabeth B Claus; Ossama Al-Mefty; Mark D Johnson; Alexandra J Golby; Ian F Dunn; E Antonio Chiocca; Lorenzo Trippa; Sandro Santagata; Rebecca D Folkerth; Philip Kantoff; Barrett J Rollins; Neal I Lindeman; Patrick Y Wen; Azra H Ligon; Rameen Beroukhim; Brian M Alexander; Keith L Ligon Journal: Neuro Oncol Date: 2015-03-09 Impact factor: 12.300
Authors: R G Weber; J Boström; M Wolter; M Baudis; V P Collins; G Reifenberger; P Lichter Journal: Proc Natl Acad Sci U S A Date: 1997-12-23 Impact factor: 11.205
Authors: Manish K Aghi; Bob S Carter; Garth R Cosgrove; Robert G Ojemann; Sepideh Amin-Hanjani; Robert L Martuza; William T Curry; Fred G Barker Journal: Neurosurgery Date: 2009-01 Impact factor: 4.654
Authors: Daniel C Bowers; Yan Liu; Wendy Leisenring; Elizabeth McNeil; Marilyn Stovall; James G Gurney; Leslie L Robison; Roger J Packer; Kevin C Oeffinger Journal: J Clin Oncol Date: 2006-11-06 Impact factor: 50.717
Authors: David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues Journal: Acta Neuropathol Date: 2007-07-06 Impact factor: 17.088
Authors: Wenya Linda Bi; Peleg Horowitz; Noah F Greenwald; Malak Abedalthagafi; Pankaj K Agarwalla; Wiliam J Gibson; Yu Mei; Steven E Schumacher; Uri Ben-David; Aaron Chevalier; Scott Carter; Grace Tiao; Priscilla K Brastianos; Azra H Ligon; Matthew Ducar; Laura MacConaill; Edward R Laws; Sandro Santagata; Rameen Beroukhim; Ian F Dunn Journal: Clin Cancer Res Date: 2016-10-05 Impact factor: 12.531
Authors: Craig Horbinski; Keith L Ligon; Priscilla Brastianos; Jason T Huse; Monica Venere; Susan Chang; Jan Buckner; Timothy Cloughesy; Robert B Jenkins; Caterina Giannini; Roger Stupp; L Burt Nabors; Patrick Y Wen; Kenneth J Aldape; Rimas V Lukas; Evanthia Galanis; Charles G Eberhart; Daniel J Brat; Jann N Sarkaria Journal: Neuro Oncol Date: 2019-12-17 Impact factor: 12.300
Authors: Ganesh M Shankar; Malak Abedalthagafi; Rachael A Vaubel; Parker H Merrill; Naema Nayyar; Corey M Gill; Ryan Brewster; Wenya Linda Bi; Pankaj K Agarwalla; Aaron R Thorner; David A Reardon; Ossama Al-Mefty; Patrick Y Wen; Brian M Alexander; Paul van Hummelen; Tracy T Batchelor; Keith L Ligon; Azra H Ligon; Matthew Meyerson; Ian F Dunn; Rameen Beroukhim; David N Louis; Arie Perry; Scott L Carter; Caterina Giannini; William T Curry; Daniel P Cahill; Frederick G Barker; Priscilla K Brastianos; Sandro Santagata Journal: Neuro Oncol Date: 2017-04-01 Impact factor: 12.300
Authors: Suganth Suppiah; Farshad Nassiri; Wenya Linda Bi; Ian F Dunn; Clemens Oliver Hanemann; Craig M Horbinski; Rintaro Hashizume; Charles David James; Christian Mawrin; Houtan Noushmehr; Arie Perry; Felix Sahm; Andrew Sloan; Andreas Von Deimling; Patrick Y Wen; Kenneth Aldape; Gelareh Zadeh Journal: Neuro Oncol Date: 2019-01-14 Impact factor: 12.300
Authors: Michael A Mooney; Wenya Linda Bi; Jonathan M Cantalino; Kyle C Wu; Thomas C Harris; Lucas L Possatti; Parikshit Juvekar; Liangge Hsu; Ian F Dunn; Ossama Al-Mefty; Phillip M Devlin Journal: J Neurooncol Date: 2019-11-19 Impact factor: 4.130
Authors: Robin A Buerki; Craig M Horbinski; Timothy Kruser; Peleg M Horowitz; Charles David James; Rimas V Lukas Journal: Future Oncol Date: 2018-08-07 Impact factor: 3.404
Authors: Malak Abedalthagafi; Wenya Linda Bi; Ayal A Aizer; Parker H Merrill; Ryan Brewster; Pankaj K Agarwalla; Marc L Listewnik; Dora Dias-Santagata; Aaron R Thorner; Paul Van Hummelen; Priscilla K Brastianos; David A Reardon; Patrick Y Wen; Ossama Al-Mefty; Shakti H Ramkissoon; Rebecca D Folkerth; Keith L Ligon; Azra H Ligon; Brian M Alexander; Ian F Dunn; Rameen Beroukhim; Sandro Santagata Journal: Neuro Oncol Date: 2016-01-28 Impact factor: 12.300